Heat Biologics (HTBX) Announces $1.5M Loan Paydown Following Warrant Exercise
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Heat Biologics, Inc. (“Heat”) (Nasdaq: HTBX) announced that it has paid down $1.5 million on its commercial loan following the recent exercise of warrants, which have generated $2.8 million in cash proceeds last quarter.
“We continue to strengthen our balance sheet and carefully manage expenses while pursuing an aggressive clinical program that will generate four important data readouts this quarter,” commented Jeff Wolf, Heat’s Founder and CEO.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
- Apple files $1 billion lawsuit against chip supplier Qualcomm
- Valhi, Inc. (VHI) Names Robert D. Graham as President and CEO
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!